Preimplantation factor (PIF) is a pregnancy specific peptide with immune modulatory properties 11 exerted on the human endometrium. Viable bovine embryos secrete PIF, but its effect on the 12 bovine endometrial immune response is unknown, both in native and inflammatory stimulated 13 endometrial tissue. An ex vivo bovine endometrial tissue culture model was used with 14 lipopolysaccharide (LPS) as an inflammatory stimulant. The effect of synthetic PIF (sPIF) was 15 assessed, in three separate experiments, on the secretion or mRNA expression of essential 16 prostaglandins and cytokines. Radioimmunoassays were used to assess prostaglandin secretion 17 and ELISA for IL-6 secretion from endometrial explants. mRNA expression of IL6 and IL8 was 18 analysed from endometrial explants with real-time PCR. Synthetic PIF reduced native IL-6 19 secretion from explants when pre-treated for 24 hours. There was no effect of sPIF on IL-6 20 secretion from LPS challenged explants; however, sPIF increased IL6 mRNA expression when 21 challenged with 500 ng/mL LPS. There was no effect of sPIF on prostaglandin secretion or 22 mRNA expression of IL8. Therefore, sPIF is able to modulate the native IL-6 production 23 pathway in the bovine endometrium, yet demonstrates no effect on prostaglandin secretion or IL8 24 expression. Unlike in human studies, effects of sPIF were minimal, thus sPIF is not an effective 25 modulator of the immune targets investigated in the bovine endometrium. 26
Preimplantation factor (PIF) is a 15 amino acid peptide that is produced by viable embryos as 31 early as the two-cell stage [1] . Bovine embryos produce PIF both pre-and post-implantation [1, 32 2 ]. Preimplantation factor works through an immune tolerance pathway in human pregnancy to 33 facilitate the acceptance of the embryo by the mother [3, 4] . It is the action of this pathway that is 34 of interest to studies of disease, as sPIF may have potential as an immune modulator. Applied to 35 healthy human endometrium, sPIF is able to upregulate secretion of several interleukins, 36
including IL-8 and IL-6 of decidualized stromal cells [5] . Interestingly, within a murine multiple 37 sclerosis model, sPIF decreased the secretion of IL-6 from splenocytes in culture showing a 38 tissue specific role of the peptide [6] . In a preliminary study, sPIF was investigated in an equine 39 model of E. coli post-mating induced endometritis. It was shown that sPIF was able to reduce 40 prostaglandin F 2α (PGF 2α ) secretion from LPS induced explants 24 hours after challenge [7] but 41 only in mares of the follicular stage of the oestrous cycle. More recently, in CD14+ cells, it has 42 been demonstrated that sPIF does not directly interact with TLR-4, but specific downstream 43 targets within the TLR-4 pathway [8] . As sPIF has been demonstrated to interact with the human 44 endometrium in an immune modulatory manner, it was proposed that the peptide may act in a 45 similar manner in the bovine endometrium. Furthermore, as uterine inflammation is a common 46 cause of infertility in cattle through a dysregulation of endocrine function [9] , it is of interest to 47 investigate the role of sPIF as an immune modulator in an endometrial inflammatory 48 environment. 49
Previous studies have utilised an ex vivo bovine model of normal and inflammatory 50 endometrium, which shows responses similar to the whole cow [10, 11] and so this model 51 provides a basis for this initial investigation. Both prostaglandins and interleukins are secreted by 52 M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 cyclic, pregnant and inflammatory endometrial tissue and so have previously been used as targets 53 to measure in ex vivo studies [10] [11] [12] . Prostaglandins are eicosanoid hormones produced by the 54 endometrium and have essential functional roles in the bovine oestrous cycle and pregnancy [13, 55 14 ]. Furthermore, both PGF 2α and prostaglandin E 2 (PGE 2 ) are involved in the endometrial 56 inflammatory response. Following a challenge with Escherichia coli-derived lipopolysaccharide 57 (LPS), there is an increase in secretion of PGF 2α and PGE 2 from endometrial tissue explants [12, 58 15] . Interleukins, such as IL-6 and IL-8 are demonstrated to be expressed during the oestrous 59 cycle [16] . Furthermore, in ex vivo studies, IL-6 and IL-8 have been shown to have key roles 60 within the endometrial innate immune response [11, 17] . 61
The aim was to investigate the use of sPIF as a potential immune modulator within the 62 bovine endometrium by assessing the role of the peptide using a previously developed 63 endometrial tissue model, using LPS treatment to model an E. coli challenge [11, 12, 15] . It has 64 already been demonstrated that sPIF does not bind to LPS [8] . It was hypothesised that sPIF 65 would reduce key immune (IL-6 and IL-8) and endocrine (PGF 2α and PGE 2 ) factors in the bovine 66 endometrium, at both a native and inflammatory level. 67
Materials and methods

68
Sample collection and endometrial explant culture 69
As these experiments used post-slaughter material, licencing through the Animals (Scientific 70 Procedures) Act 1986 and ethical review were not necessary. Bovine uteri and corresponding 71 blood samples were collected from cows presented for slaughter at a local abattoir. A total of 46 72 animals were used in the study. Uteri with stage I and IV ovaries were investigated to allow the 73 study of sPIF on endometrial tissues that were not under the immune suppressive effects of [18, 19] . Samples were staged by assessing ovarian morphology as previously 75 described [20, 21] . Briefly, stage I was defined as having a newly ruptured corpus luteum with a 76 diameter of 0.5 -1.5 cm and stage IV as having a regressing corpus luteum with a diameter of < 77 1 cm [20] . 78
Uteri and blood samples were stored on ice during the one-hour transportation to the 79 laboratory. Tissues were used for explant culture and blood serum for analysis of progesterone 80 concentration via ELISA (DRG Diagnostics, Marburg, Germany). To support ovarian 81 morphology staging, the blood sera were used for progesterone analysis. For stage I and IV uteri, 82 samples were deemed to have high progesterone if serum concentrations were above 1 ng/mL 83 [10] . Progesterone inter-and intra-assay CVs were 8.66 % and 2.18 %, respectively. 84
Tissue culture was established using the method previously described [11] . Briefly, tissue 85 was sampled from the uterine horn ipsilateral to the staged ovary using an 8 mm biopsy punch. 86
Samples were weighed and placed in 6 well plates (Corning, Amsterdam, The Netherlands) with 87 3 mL of RPMI 1640 media (Gibco, Life Technologies, Paisley, UK) supplemented with 50 88 IU/mL penicillin, 50 µg/mL streptomycin (Sigma-Aldrich, St. Louis, MO, USA) and 2.5 µg/mL 89 amphotericin B (Sigma-Aldrich). All treatments were run in duplicate or triplicate and described 90 for each experiment. Explants were incubated in a sterile incubator at 37 o C and 5 % CO 2 for up 91 to 72 hours. Ultra-pure LPS from E. coli 0111:B4 strain was used (InvivoGen, Toulouse, 92 France). Synthetic PIF (MVRIKPGSANKPSDD) was synthesised with > 95 % purity by 93 Bioincept (New Jersey, USA). The amino acid structure of the human 15 amino acid PIF has 94 previously been analysed and the 3D structure predicted [22] . The sPIF used in the present study 95 is utilised in all research investigating sPIF. 96
The aim of experiment 1 was to investigate the effect of sPIF on prostaglandin and IL-6 secretion 98 from bovine endometrial explants with and without an LPS challenge. Bovine stage IV uteri 99 (n=14) were utilised. Preliminary studies from our laboratory, utilising unidentified cattle breeds, 100 showed varied results in terms of prostaglandin secretion following sPIF treatment. Therefore, 101 cattle were separated into two groups at the abattoir through identification of being either: beef 102 heifers (n=7), unlikely to have been pregnant or; dairy type cows (n=7) and having had one or 103 more pregnancies. Tissues were sampled from the endometrium and challenged with the 104 following treatments in triplicate: control (media alone); LPS (1 µg/mL) alone; sPIF at three 105 concentrations (50, 100 or 500 nM); or LPS (1 µg/mL) combined with each of the three sPIF 106 concentrations. The LPS concentration was chosen based on previous studies utilising the same 107 endometrial tissue model [11, 12] . Synthetic PIF concentrations were based on the previously 108 described physiological range within the circulation during human pregnancy (50 and 100 nM) 109 and one supra-physiological concentration (500 nM) [23] . Media supernatants were sampled 24, 110 48 and 72 hours after challenge, from the same well at each time point. Time points of 24 and 48 111 hours were chosen based on previous studies [11, 12] and 72 hours based on an equine 112 endometrial explant study as a persistent infection time point [24] . Supernatant samples were 113 stored at -20 o C until analysed for PGF 2α , PGE 2 and IL-6. 114
Experiment 2 115
The aim of experiment 2 was to investigate the effect of a pre-treatment of sPIF on prostaglandin 116 and IL-6 secretion from bovine endometrial explants with and without an LPS challenge and to 117 ensure that there was no underlying inflammation in tracts that may cause variability in the 118 results. Bovine stage I (n=12) and stage IV (n=12) uteri were utilised, as for experiment 1, split Based on the results of experiment 1, the treatment protocol was modified so that 127 explants were pre-treated with sPIF (50, 100 or 500 nM) or media alone (if explants were not to 128 receive sPIF for the main treatment protocol) for 24 hours before challenging with LPS. At the 129 end of the pre-treatment, the media supernatants were aspirated and replaced with fresh media 130 alone or containing sPIF (50, 100 or 500 nM) or LPS (1 µg/mL) treatments as in experiment 1. 131 Supernatant was sampled at 24 and 48 hours from different explant wells. No samples were 132 collected 96 hours after the beginning of the pre-treatment (72 hours after LPS challenge) 133 because integrity of tissue is likely to be compromised in serum free culture beyond 72 hours. 134 Supernatant samples were stored at -20 o C until analysed for PGF 2α , PGE 2 and IL-6. 135
Experiment 3 136
The aim of experiment 3 was to investigate the effect of a pre-treatment of sPIF on prostaglandin 137 and IL-6 secretion and IL6 and IL8 mRNA expression in bovine endometrial explants, with and 138 without three low dose LPS challenges to induce a less severe inflammatory response. Bovine 139 stage I (n=4) and stage IV (n=4) uteri were utilised. Only tracts from cows (at least 1 previous 140 pregnancy) were used. As in experiment 2, all tracts were swabbed using the cytobrush technique M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 8 and cytology examined for each tract to establish if there was any underlying inflammation. Any 142 animals with greater than 5% PMNs present were discarded. 143
A 24 hour pre-treatment of sPIF or media alone was used, as in experiment 2. Based on 144 the results of experiment 1 and 2 the treatment choices were modified to use lower 145 concentrations of LPS (5, 50, 500 ng/mL). Although 1 µg/mL of LPS is a more commonly used 146 dose in previous endometrial explant studies, these concentrations of LPS have also previously 147 been shown to significantly induce PGF 2α , PGE 2 and IL-6 secretion from bovine endometrial 148 explants or cells [11, 12] . One concentration of sPIF (100 nM) was used based on results from 149 experiment 2. Explants were harvested 6 hours after treatment for determination of mRNA 150 expression of IL6 and IL8. Supernatant was collected 24 hours after treatment from separate 151 wells to determine IL-6 secretion. 152
Prostaglandin radioimmunoassay and IL-6 ELISA 153
Supernatant samples were analysed for PGF 2α and PGE 2 by radioimmunoassay (RIA) as 154 described previously [28] . Antisera were a kind gift from Professor N. Poyser, University of 155 Edinburgh and Professor Claire Wathes, The Royal Veterinary College. The limits of detection 156 were 0.02 ng/mL for both assays. PGF 2α inter-and intra-assay CVs were 12.8 % and 2.19 %, 157 respectively. PGE 2 inter-and intra-assay CVs were 12.69 % and 6.71 %, respectively. 158 Supernatant samples were analysed for IL-6 concentration as described by the 159 manufacturer (Bovine IL-6 ELISA; Thermo Fisher Scientific). The limit of detection was 75 160 pg/mL and inter-and intra-assay CVs were 8.19 % and 5.99 %, respectively. Green RT-PCR, using Maxima SYBR Green/Rox qPCR master mix (Thermo Fisher Scientific) 170 on a CFX connect (Bio-Rad, Hemel Hempstead, UK). Gene expression was normalised to two 171 housekeeping genes, ACTB and 18s (of which expression was not altered by the experimental 172 treatments) and then the control sample. All primers are outlined in Table 1 . 173
Statistical analysis 174
Data were analysed using GenStat statistical software (14 th edition, VSN International, Hemel 175 Hempstead, UK) and reported as mean ± standard error of the mean (SEM). RIA and ELISA 176 data were expressed as prostaglandin (ng) or interleukin (pg) secretion per mg of tissue, 177 respectively and grouped into high or low progesterone groups where appropriate. Skewed data 178 were transformed using log+1 or square root transformations in order to make the data normally 179 distributed. Ratios of PGF 2α to PGE 2 secretion were calculated from the raw data within each 180 experiment where prostaglandins were measured. Statistical significance was set at P<0.05 for all 181 analyses and least significant difference (LSD) used as a post hoc significance test. A statistical 182 tendency was defined as 0.05 < P < 0.1. The following analyses were completed for each 183 experiment.
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10 For experiment 1, a repeated measures ANOVA was performed to assess the effects of 185 treatment, cattle type, progesterone and time. Cows were fitted as a random effect and time point 186 as the repeated measure. Treatment and progesterone were initially used as the main treatments. 187
Once it was established that there was no effect of progesterone, progesterone was removed as a 188 main treatment. Treatment and cattle type were used as the main treatments for the main 189 statistical analysis. There was no interaction between sPIF treatment and cattle type (P>0.05) for prostaglandin or 207 IL-6 secretion. LPS challenge increased (P<0.001) PGF 2α , PGE 2 and IL-6 secretion from 208 explants at all time points (Fig 1) . Synthetic PIF did not affect (P>0.05) PGF 2α , PGE 2 or IL-6 209 secretion from explants with or without a LPS challenge (Fig 1) . Synthetic PIF treatment had no 210 effect on the ratio between PGF 2α and PGE 2 (P>0.05) at all time points, although LPS treatment 211 alone increased the ratio, meaning that PGE 2 secretion was favoured over PGF 2α (P<0.05; data 212 not shown). In explants not stimulated with LPS, IL-6 secretion was lower (P<0.05) with 213 treatment of 100 nM sPIF compared with the 50 nM and 500 nM treatments (Fig 1c) . 214
Experiment 2 215
Cytobrush smears showed that no cattle had subclinical inflammation as all samples had less 216 than 5 % PMN. 217
Serum progesterone concentrations 218
Stage I samples were assigned to the luteal high progesterone (LHP) group if progesterone 219 concentrations were greater than 1 ng/mL (n=6), with the remaining samples allocated to a luteal 220 low progesterone (LLP) group (n=6). Mean progesterone concentrations for LLP and LHP were 221 0.66 ± 0.19 ng/mL and 8.2 ± 4.84 ng/mL, respectively. 222
Stage IV samples were allocated to a follicular high progesterone (FHP) group if 223 progesterone concentrations were greater than 1 ng/mL (FHP; n=7) with the remaining samples 224 assigned to a follicular low progesterone group (FLP; n=5). Mean progesterone concentrations 225 for FLP and FHP were 0.56 ± 0.13 ng/mL and 9.61 ± 3.18 ng/mL, respectively.
There was no effect of progesterone on PGF 2α , PGE 2 or IL-6 secretion within either stage 227 I or IV explants (P>0.05). Therefore, the factor of progesterone was removed and results 228 displayed together. However, there was an interaction between progesterone group and 229 treatments for PGF 2α secretion in Stage I tissue at the 24 hour time point, with PGF 2α secretion 230 being significantly lower from LPS and PIF treated explants in the LLP group, compared to the 231 equivalent treatments in the HLP group (P<0.05; data not shown). This particular interaction did 232 not manifest itself in any of the other experiments. 233
Prostaglandin F 2α , E 2 and IL-6 secretion from endometrial tissue 234
There was no interaction (P>0.05) between sPIF treatment and cattle type in stage I cattle. LPS 235 induced secretion (P<0.001) of PGF 2α , PGE 2 and IL-6 from explants at both 24 and 48 hours (Fig  236   2 ). There was no effect (P<0.05) of sPIF on PGF 2α or PGE 2 secretion, with or without the 237 presence of LPS (Fig 2) . Synthetic PIF treatment of 50 and 100 nM reduced (P<0.05) the PGF 2α 238 to PGE 2 secretion ratio compared with the control at 24 hours (Table 2) , but not after 48 hours 239 (P>0.05). The 500 nM sPIF treatment had no effect (P>0.05) on the PGF 2α to PGE 2 secretion 240 ratio at either time point (Table 2) . At 24 hours LPS treatment alone did not increase the PGF 2α 241 to PGE 2 secretion ratio compared with the control, but LPS with 100 nM sPIF treatments did 242 increase (P<0.05) the ratio from the control (Table 2) . At 48 hours, LPS alone and in 243 combination with all sPIF treatments increased (P<0.05) the PGF 2α to PGE 2 secretion ratio 244 compared with the control (Table 2) . Synthetic PIF at 100 and 500 nM reduced (P<0.05) native 245 IL-6 secretion from unchallenged explants compared with the control at 24 hours (Fig 2c) , but 246 not at 48 hours (P>0.05; Fig 2f) . There was no effect (P>0.05) of sPIF on IL-6 secretion from 247 LPS stimulated explants (Fig 2) . 248
In Stage IV cattle, there was no interaction (P>0.05) between sPIF treatment and cattle 249 type. As with Stage I cattle, LPS induced (P<0.001) PGF 2α , PGE 2 and IL-6 secretion from 250 explants at both 24 and 48 hours (Fig 3) . There was no effect (P>0.05) of sPIF on PGF 2α or PGE 2 251 secretion with or without the presence of LPS (Fig 3) . Synthetic PIF alone had no effect (P>0.05) 252 on the PGF 2α to PGE 2 secretion ratio (Table 3) . At both time points, LPS alone and with all sPIF 253 treatments increased (P<0.05) the PGF 2α to PGE 2 secretion ratio compared with the control 254 (Table 3) . However, as with Stage I cattle, sPIF at 100 nM reduced (P<0.05) IL-6 secretion 255 compared with the control at 24 hours from explants that were not challenged with LPS (Fig 3c) , 256 but not at 48 hours (P>0.05; Fig 3f) . There was no effect of sPIF on LPS stimulated explants 257 (P>0.05; Fig 3) . 258
Experiment 3 259
Cytobrush smears showed no cattle to have subclinical inflammation as all samples had less than 260 5% PMN. There was no effect of progesterone on PGF 2α , PGE 2 or IL-6 secretion within either stage 271 of cycle (P>0.05). Therefore, the factor of progesterone was removed and results displayed 272 together. 273 3.3.2 Expression of IL6 and IL8 in endometrial tissue 274 IL6 and IL8 expression were increased (P<0.05) in both stage I and IV tissue following 50 and 275 500 ng/mL LPS treatments (Fig 4) . The treatment of 5 ng/mL LPS increased (P<0.01) IL6 gene 276 expression in stage I tissue (Fig 4a) . There was no effect (P>0.05) of 5 ng/mL LPS treatment on 277 IL6 expression in stage IV tissue or IL8 expression in any tissue (Fig 4b, c, d) . 278
In stage IV tissue, when sPIF was added with 500 ng/mL LPS, IL6 gene expression was 279 increased (P<0.05) compared with the expression induced by 500 ng/mL LPS treatment alone 280 (Fig 4c) . However, there was no effect (P>0.05) of sPIF treatment in combination with any other 281 concentration of LPS or in the control samples in stage I or stage IV tissue (Fig 4a, c) . 282
Furthermore, there was no effect (P>0.05) of sPIF on IL8 expression in control or LPS treated 283 samples (Fig 4b, d) . 284 3.3.3 IL-6 secretion from endometrial tissue 285 IL-6 secretion from tissue not stimulated with LPS in stage I tissue was undetectable. All three 286 concentrations of LPS induced (P<0.05) IL-6 secretion from stage IV explants at 24 hours (Fig  287   5b ). Only 50 and 500 ng/mL LPS treatments induced (P<0.001) IL-6 secretion from stage I 288 explants (Fig 5a) . There was no effect (P>0.05) of sPIF on IL-6 secretion from explants with or 289 without LPS treatment ( Fig 5) . However, there was a statistical tendency (P<0.1) for sPIF to 290 decrease IL-6 secretion from the 500 ng/mL LPS treatment in stage IV tissue only. 
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Discussion
292
This is the first study to investigate the effects of sPIF within the bovine endometrium. Although 293 by a small amount, sPIF significantly reduced IL-6 secretion from unstimulated stage I and stage 294 IV endometrial explants when using a pre-treatment of sPIF, but not from LPS challenged 295 explants. Conversely, sPIF increased IL6 mRNA expression from explants challenged with LPS, 296 demonstrating possible differential effects of sPIF on mRNA expression and protein secretion, 297 which needs further elucidation. There was no effect of sPIF on prostaglandin secretion from 298 explants with or without LPS challenge. Heifers were separated from parous cows and cytobrush 299 analysis on all tracts exhibited < 5% PMN, therefore any lack of effect was not attributed to 300 whether the animal had previously been pregnant or had active inflammation in the uterus, A 24 hour pre-treatment period was required to obtain an effect of sPIF on IL-6 secretion 330 compared to the control. Previous human based studies have not used pre-treatment, but treated 331 with sPIF for up to 24 hours [3, 5] . Yet, work on the human endometrium has only been 332 completed on decidualized cells, which constitute the native environment for PIF within 333 pregnancy [3, 5] . Decidua may be more responsive to sPIF as they are pregnancy specific. It is 334 postulated that cyclic endometrial cells, not recently exposed to pregnancy signals, need a period 335 of sPIF priming so that the peptide is able to modulate the uterine immune response. 336
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When examining the effect of sPIF on LPS stimulated prostaglandin or IL-6 secretion in 337 the present study, sPIF had no effect. Synthetic PIF has previously been shown to reduce nitric 338 oxide production by macrophages, following LPS stimulation [31, 37] , but this is the first study 339 to investigate the effect of sPIF on the cytokine or prostaglandin secretion from the endometrium 340 following LPS stimulation. As sPIF reduced native IL-6 secretion from tissue, it was considered 341 whether the concentration of LPS was too high; a concentration of 1 µg/mL LPS may induce an 342 acute immune response too extreme for sPIF to have an effect. Therefore, experiment 3 utilised 343 three lower LPS concentrations based on a previous bovine endometrial explant study (5, 50 or 344 500 ng/mL) [11] . There was no effect of sPIF on IL-6 secretion when explants were stimulated 345 with these lower LPS concentrations, yet stage IV IL6 mRNA expression was up-regulated 346 following treatment with sPIF and 500 ng/mL LPS. Moreover, in the same tissue, there was a 347 statistical tendency for sPIF to decrease IL-6 secretion. Samples were collected at different time TLR-4 dependent manner through the phosphatidylinositol-3 kinase/Akt pathway and 361 subsequent destabilisation of the KH-type splicing regulatory protein, which also regulates 362 several other miRNAs [31] . Such mechanisms of sPIF should be further studied in the bovine 363 endometrium to assess the differential effects of sPIF on IL6 mRNA expression and subsequent 364 protein secretion. 365
There was no effect of sPIF on IL8 mRNA expression in experiment 3, with or without 366 LPS treatment. Within decidualized human endometrial stromal cells, sPIF up-regulated IL-8 367 protein secretion to a greater extent than that of IL-6 in the same study [5] . The disagreement 368
with the present study may be due to one of several factors. Firstly, the cellular response to sPIF 369 may be different, the present study used cyclic bovine endometrial tissue, whereas previous 370 studies used decidualized human cells [5] . Additionally, the present study used whole tissue 371 comprised of epithelial and stromal cells, compared with a culture of isolated stromal cells as 372 used in human studies [5] . 373
In the context of sPIF as an immune modulator within the bovine endometrium, the 374 evidence provided here shows that sPIF has limited effects. Nonetheless, it would be of interest 375 to determine the response of bovine endometrial stromal cells alone to sPIF, because postpartum 376 stromal cells are intermittently exposed through the syndesmochorial placenta in bovine 377 pregnancy. 378
In conclusion, although to a small extent, sPIF significantly reduced native IL-6 secretion 379 from healthy stage I and IV bovine endometrial explants following a 24 hour pre-treatment with 380 sPIF. Furthermore, when stage IV explants were stimulated with 500 ng/mL LPS, sPIF increased M A N U S C R I P T
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IL6 mRNA expression at 6 hours post treatment, following an initial 24 hour pre-treatment. 382
There was no effect of sPIF on prostaglandin secretion from endometrial explants. Therefore, the 383 present study demonstrates limited effects of the ability of sPIF to modulate key immune factors 384 of bovine endometrial tissue. • A 24 hour pre-treatment with sPIF was needed to exert effects on the endometrium.
• sPIF reduced native IL-6 secretion from the endometrium.
• sPIF increased IL6 gene expression in LPS stimulated endometrial tissue.
• There was no effect of sPIF on prostaglandin secretion or IL8 expression.
